Thesis (M.Sc.(Dietetics))--University of Pretoria, 2009. / Abstract in English. Includes bibliographical references.

Thesis (Ph. D.)--Drexel University, 2007. / Includes abstract and vita. Includes bibliographical references (leaves 111-145).

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A AIDS deixou de ser uma doença aguda, tendo como desfecho morte imediata. Com o advento da terapia antirretroviral potente, controlou-se o vírus da imunodeficiência humana, tornando a AIDS uma doença crônica. Entretanto, a terapia antirretroviral potente possui reações adversas, sendo uma delas a síndrome lipodistrófica do HIV. Uma das manifestações desta síndrome é a lipoatrofia facial: perda de gordura na face. O Ministério da Saúde do Brasil normatizou a aplicação de polimetilmetacrilato para reabilitação da face. Porém, crianças e adolescentes não podem realizar tal procedimento. Para esta população, o presente trabalho propõe a terapia miofuncional. Objetivo: Verificar os efeitos da terapia fonoaudiológica miofuncional em adolescentes vivendo com HIV/AIDS, contraído por transmisão vertical, com lipoatrofia facial. Métodos: Realizou-se avaliação fonoaudiológica antes e depois de 12 sessões de terapia fonoaudiológica, utilizando avaliação estrutural, medidas antropométricas da face, registro fotográfico, peso e altura, índice de lipoatrofia facial (ILA) e índice de incapacidade facial índice de bem-estar social (IIF-IBES). Na terapia fonoaudiológica, utilizou-se exercícios isotônicos e isométricos para face, bochechas e língua. Foram coletados os últimos dados, como a contagem de CD4, a carga viral, e o histórico da terapia antirretroviral utilizada. Resultados: Dos 15 pacientes estudados, 10 tinham lipoatrofia facial, mensurada através do ILA. Quatro completaram as todas as sessões de terapia fonoaudiológica. Nestes pacientes, as medidas antropométricas da face ficaram mais harmônicas, corroborando com os achados do registro fotográfico e da avaliação estrutural. Aumentou-se sutilmente o ILA em três pacientes. Conclusão: A terapia fonoaudiológica mostrou-se eficaz no tratamento da lipoatrofia facial leve. Considera-se importante a readequação das funções estomatognáticas quando necessário. Outras demandas fonoaudiológicas surgiram na população estudada. / Nowadays, AIDS is no longer an acute disease that leads to immediate death. Since the discovery of a highly active antiretroviral therapy, the human immunodeficiency virus is likely to be controlled, so that AIDS became a chronic state. Nevertheless, such a treatment gave rise to adverse reactions such as, for instance, HIV-associated lipodystrophy. Among the signs resulting from this syndrome, patients may present facial lipoatrophy, namely a loss of fat in the face. In these cases, Brazilian Ministry of Health determined the mandatory application of polymethyl metacrylate for the reconstitution of the face. However, considering that neither children nor teenagers are able to undergo such a procedure, the present work proposes a myofunctional therapy to this specific population. Objective: To assess the effects of myofunctional therapy on teenagers living with HIV/AIDS, who were infected through vertical transmission and present facial lipoatrophy. Methods: A speech language pathology assessment was performed before and after 12 speech-language pathology therapeutic sessions, by using structural evaluation, anthropometic measurements of the face, photographic registration, weight and height, as well as facial lipoatrophy index (ILA), and both facial disability - social well-being indexes (IIF-IBES). During the speech-language pathology treatment, patients were submitted to isotonic and isometric exercises for the face, cheeks and tongue. Then, we obtained the last data, such as CD4 count, viral load, and also checked the history of antiretroviral therapy that was administrated. Results: Among 15 patients studied, 10 presented facial lipoatrophy, as measured through ILA. Four of them completed all the speech language pathology therapeutic sessions. In these patients, the anthropometric measures of the face became more harmonious, thus corroborating the findings obtained from photographical registration and from structural evaluation. In three patients, ILA showed a subtle increase. Conclusion: Speech-language pathology therapy was found to be efficient to treat mild cases of facial lipoatrophy. Whenever necessary, a readaptation of stomatognathic functions is considered to be quite relevant. Besides, the studied population presented other speech language pathology requirements.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A AIDS deixou de ser uma doença aguda, tendo como desfecho morte imediata. Com o advento da terapia antirretroviral potente, controlou-se o vírus da imunodeficiência humana, tornando a AIDS uma doença crônica. Entretanto, a terapia antirretroviral potente possui reações adversas, sendo uma delas a síndrome lipodistrófica do HIV. Uma das manifestações desta síndrome é a lipoatrofia facial: perda de gordura na face. O Ministério da Saúde do Brasil normatizou a aplicação de polimetilmetacrilato para reabilitação da face. Porém, crianças e adolescentes não podem realizar tal procedimento. Para esta população, o presente trabalho propõe a terapia miofuncional. Objetivo: Verificar os efeitos da terapia fonoaudiológica miofuncional em adolescentes vivendo com HIV/AIDS, contraído por transmisão vertical, com lipoatrofia facial. Métodos: Realizou-se avaliação fonoaudiológica antes e depois de 12 sessões de terapia fonoaudiológica, utilizando avaliação estrutural, medidas antropométricas da face, registro fotográfico, peso e altura, índice de lipoatrofia facial (ILA) e índice de incapacidade facial índice de bem-estar social (IIF-IBES). Na terapia fonoaudiológica, utilizou-se exercícios isotônicos e isométricos para face, bochechas e língua. Foram coletados os últimos dados, como a contagem de CD4, a carga viral, e o histórico da terapia antirretroviral utilizada. Resultados: Dos 15 pacientes estudados, 10 tinham lipoatrofia facial, mensurada através do ILA. Quatro completaram as todas as sessões de terapia fonoaudiológica. Nestes pacientes, as medidas antropométricas da face ficaram mais harmônicas, corroborando com os achados do registro fotográfico e da avaliação estrutural. Aumentou-se sutilmente o ILA em três pacientes. Conclusão: A terapia fonoaudiológica mostrou-se eficaz no tratamento da lipoatrofia facial leve. Considera-se importante a readequação das funções estomatognáticas quando necessário. Outras demandas fonoaudiológicas surgiram na população estudada. / Nowadays, AIDS is no longer an acute disease that leads to immediate death. Since the discovery of a highly active antiretroviral therapy, the human immunodeficiency virus is likely to be controlled, so that AIDS became a chronic state. Nevertheless, such a treatment gave rise to adverse reactions such as, for instance, HIV-associated lipodystrophy. Among the signs resulting from this syndrome, patients may present facial lipoatrophy, namely a loss of fat in the face. In these cases, Brazilian Ministry of Health determined the mandatory application of polymethyl metacrylate for the reconstitution of the face. However, considering that neither children nor teenagers are able to undergo such a procedure, the present work proposes a myofunctional therapy to this specific population. Objective: To assess the effects of myofunctional therapy on teenagers living with HIV/AIDS, who were infected through vertical transmission and present facial lipoatrophy. Methods: A speech language pathology assessment was performed before and after 12 speech-language pathology therapeutic sessions, by using structural evaluation, anthropometic measurements of the face, photographic registration, weight and height, as well as facial lipoatrophy index (ILA), and both facial disability - social well-being indexes (IIF-IBES). During the speech-language pathology treatment, patients were submitted to isotonic and isometric exercises for the face, cheeks and tongue. Then, we obtained the last data, such as CD4 count, viral load, and also checked the history of antiretroviral therapy that was administrated. Results: Among 15 patients studied, 10 presented facial lipoatrophy, as measured through ILA. Four of them completed all the speech language pathology therapeutic sessions. In these patients, the anthropometric measures of the face became more harmonious, thus corroborating the findings obtained from photographical registration and from structural evaluation. In three patients, ILA showed a subtle increase. Conclusion: Speech-language pathology therapy was found to be efficient to treat mild cases of facial lipoatrophy. Whenever necessary, a readaptation of stomatognathic functions is considered to be quite relevant. Besides, the studied population presented other speech language pathology requirements.

A introdução da terapia anti-retroviral de alta potência no tratamento da infecção pelo HIV reduziu significativamente as taxas de morbi-mortalidades relacionadas à imunodeficiência. Entretanto, o tratamento medicamentoso é acompanhado de vários efeitos colaterais, dentre eles, a síndrome da lipodistrofia (SL), caracterizada por alterações morfológicas e metabólicas. Apesar de sua patogenia não estar totalmente esclarecida, é sabido que aumento dos níveis de algumas citocinas inflamatórias estão relacionados com o desenvolvimento da SL. Diversos sítios polimórficos têm sido descritos por influenciarem a transcrição de genes, levando a variações nos níveis de produção de citocinas, como os da região promotora da interleucina-18 (IL-18 -607 C/A e IL-18 -137 C/G) e do gene do interferon gama (IFN- +874 T/A). Diante disso, esse estudo tipificou os polimorfismos da IL-18 e do IFN- em 88 pacientes portadores do HIV com a SL, em 79 portadores do HIV sem a SL, todos sob terapia anti-retroviral e em 133 indivíduos saudáveis, por meio da técnica de reação em cadeia da polimerase com iniciadores de seqüência específica. Este estudo foi aprovado pelo Comitê de Ética em Pesquisa. A presença do alelo -607A e do genótipo -607AA na IL-18 estava significativamente aumentada nos pacientes portadores do HIV com SL quando comparados aos sem a SL, conferindo susceptibilidade ao desenvolvimento da síndrome. De maneira oposta, o alelo -607C e o genótipo -607CC estavam significativamente aumentados em pacientes portadores do HIV sem SL quando comparados aos com a SL, conferindo proteção ao desenvolvimento da síndrome. Os haplótipos -137G/-607A and -137C/-607A, que comportam o alelo -607A, também estavam associados com a susceptibilidade à SL e o haplótipo -137G/-607C estava fortemente associado com proteção contra a SL. Nenhuma diferença significativa na distribuição alélica e genotípica da IL-18 -137 e do IFN- +874 foram observadas entre os grupos de pacientes e o grupo controle. Este é o primeiro estudo que avaliou o polimorfismo da IL-18 e do IFN- na SL e os resultados sugerem que a região promotora da IL-18 está associada com o desenvolvimento da SL em pacientes portadores do HIV. / The introduction of highly active antiretroviral therapy in the treatment of HIV infection significantly reduced the rates of morbidity and mortality related to immunodeficiency. However, the drug treatment is accompanied by various side effects, including the lipodystrophy syndrome (LD), characterized by morphological and metabolic changes. Although its pathogenesis is not totally clear, it is known that increased levels of some inflammatory cytokines are related to the development of LD. Several polymorphic sites have been described by influencing transcription of genes, leading the variations in the levels of cytokine production, such as the promoter region of interleukin-18 (IL-18 -607 C/A and IL-18 -137 C/G) and the interferon gamma gene (IFN- +874 T/A). Thus, this study typifies the polymorphism of the IL-18 and IFN- in 88 HIV-infected patients with LD, in 79 HIV-infected patients without LD, all under antiretroviral therapy and in 133 healthy controls, using the sequence-specific primers-polymerase chain reaction. This study was approved by the Ethics Committee at the place of study. The presence of -607A allele and -607AA genotype in IL-18 gene were significantly increased in HIV patients presenting LD as compared with HIV patients without LD, resulting in susceptibility to the development of LD. Conversely, the -607C allele and -607CC genotype were significantly increased in HIV patients without LD as compared with the HIV patients with LD, offering protection against LD. Haplotypes -137G/-607A and -137C/-607A, carrying the -607A allele, were also associated with susceptibility to LD. The haplotype -137G/-607C was strongly associated with protection against LD. No significant differences in IL-18 -137 and IFN- +874 genotype and allele distribution were observed in patients when compared to a control group. This is the first study evaluating the IL-18 and IFN- polymorphisms in LD and the results suggest that the promoter region of the IL-18 gene is associated with LD development in HIV-infected patients.

A introdução da terapia anti-retroviral de alta potência no tratamento da infecção pelo HIV reduziu significativamente as taxas de morbi-mortalidades relacionadas à imunodeficiência. Entretanto, o tratamento medicamentoso é acompanhado de vários efeitos colaterais, dentre eles, a síndrome da lipodistrofia (SL), caracterizada por alterações morfológicas e metabólicas. Apesar de sua patogenia não estar totalmente esclarecida, é sabido que aumento dos níveis de algumas citocinas inflamatórias estão relacionados com o desenvolvimento da SL. Diversos sítios polimórficos têm sido descritos por influenciarem a transcrição de genes, levando a variações nos níveis de produção de citocinas, como os da região promotora da interleucina-18 (IL-18 -607 C/A e IL-18 -137 C/G) e do gene do interferon gama (IFN- +874 T/A). Diante disso, esse estudo tipificou os polimorfismos da IL-18 e do IFN- em 88 pacientes portadores do HIV com a SL, em 79 portadores do HIV sem a SL, todos sob terapia anti-retroviral e em 133 indivíduos saudáveis, por meio da técnica de reação em cadeia da polimerase com iniciadores de seqüência específica. Este estudo foi aprovado pelo Comitê de Ética em Pesquisa. A presença do alelo -607A e do genótipo -607AA na IL-18 estava significativamente aumentada nos pacientes portadores do HIV com SL quando comparados aos sem a SL, conferindo susceptibilidade ao desenvolvimento da síndrome. De maneira oposta, o alelo -607C e o genótipo -607CC estavam significativamente aumentados em pacientes portadores do HIV sem SL quando comparados aos com a SL, conferindo proteção ao desenvolvimento da síndrome. Os haplótipos -137G/-607A and -137C/-607A, que comportam o alelo -607A, também estavam associados com a susceptibilidade à SL e o haplótipo -137G/-607C estava fortemente associado com proteção contra a SL. Nenhuma diferença significativa na distribuição alélica e genotípica da IL-18 -137 e do IFN- +874 foram observadas entre os grupos de pacientes e o grupo controle. Este é o primeiro estudo que avaliou o polimorfismo da IL-18 e do IFN- na SL e os resultados sugerem que a região promotora da IL-18 está associada com o desenvolvimento da SL em pacientes portadores do HIV. / The introduction of highly active antiretroviral therapy in the treatment of HIV infection significantly reduced the rates of morbidity and mortality related to immunodeficiency. However, the drug treatment is accompanied by various side effects, including the lipodystrophy syndrome (LD), characterized by morphological and metabolic changes. Although its pathogenesis is not totally clear, it is known that increased levels of some inflammatory cytokines are related to the development of LD. Several polymorphic sites have been described by influencing transcription of genes, leading the variations in the levels of cytokine production, such as the promoter region of interleukin-18 (IL-18 -607 C/A and IL-18 -137 C/G) and the interferon gamma gene (IFN- +874 T/A). Thus, this study typifies the polymorphism of the IL-18 and IFN- in 88 HIV-infected patients with LD, in 79 HIV-infected patients without LD, all under antiretroviral therapy and in 133 healthy controls, using the sequence-specific primers-polymerase chain reaction. This study was approved by the Ethics Committee at the place of study. The presence of -607A allele and -607AA genotype in IL-18 gene were significantly increased in HIV patients presenting LD as compared with HIV patients without LD, resulting in susceptibility to the development of LD. Conversely, the -607C allele and -607CC genotype were significantly increased in HIV patients without LD as compared with the HIV patients with LD, offering protection against LD. Haplotypes -137G/-607A and -137C/-607A, carrying the -607A allele, were also associated with susceptibility to LD. The haplotype -137G/-607C was strongly associated with protection against LD. No significant differences in IL-18 -137 and IFN- +874 genotype and allele distribution were observed in patients when compared to a control group. This is the first study evaluating the IL-18 and IFN- polymorphisms in LD and the results suggest that the promoter region of the IL-18 gene is associated with LD development in HIV-infected patients.

Assignment (MPhil)--University of Stellenbosch, 2006. / ENGLISH ABSTRACT: The aim of this study was to investigate practical methods of monitoring AIDS related wasting and lipodystrophy in a resource-poor clinical setting with HIV infected women as the population group of interest. Measurement of body composition changes using anthropometry is both cost- and time-efficient. Various different skinfolds were taken and two different equations (the equations of Pollock et al. (1975) and Durnin and Womersley (1974) for calculating body fat were used to determine the most promising method or methods of monitoring body composition changes in a clinical setting. Detailed anthropometric measurements were performed, as well as selected measurements for haematological parameters and quality of life (QoL) for a group of 8 participants on antiretroviral medication (ART group) and 6 participants who were not on treatment (TN group). New variables namely, intra-abdominal indicator (IAI) and a percent of ideal body mass to percent of ideal arm circumference ratio (%IBW:%IAC) were investigated as possible indicators of lipodystrophy. Although measurements were taken at various timepoints, three specific time-points were chosen for data-analysis for the ART group and two time points for the TN group. These three time-points were, baseline (on the day of recruitment for TN participants and within one month before the initiation of treatment for ART participants), short-term (2 to 12 weeks after treatment initiation or the baseline measurement or for the ART and the TN participants) and long-term (within one and a half year of treatment initiation for the ART group). ART and TN participants did not differ for many variables at baseline. The major differences between ART and TN were in measured and derived variables of the arm, especially percent of ideal arm circumference (%IAC) and upper arm fat area (UAFA), which were significantly lower in the ART group. CD4+ and QoL improved significantly for the ART participants from baseline to long-term. This was not associated with changes in muscle mass, but rather some fat mass variables. Participants on antiretroviral medication exhibited changes relating to abdominal obesity. It was concluded that antiretroviral therapy contributed greatly to the QoL of the participants and it probably aided in the recovery from wasting for at least one participant in this study. Measures of the arm can be used in a rural clinical setting to effectively monitor patients with regard to AIDS related wasting. The new variables IAI and %IBW:%IAC could be helpful in the monitoring of lipodystrophy and should be investigated in future research. / AFRIKAANSE OPSOMMING: Die doelwit van hierdie studie is om praktiese metodes te ondersoek om VIGS-verwante uittering en lipodistrofie te meet in ‘n plattelandse kliniese omgewing (waar hulpbronne dikwels beperk is) met MIV ge-infekteerde vroue as populasiegroep. Die gebruik van antropometrie om veranderinge in liggaamssamestelling te meet is beide koste- en tydeffektief. Verskeie velvoumetings is geneem en twee verskillende vergelykings (die vergelykings van Pollock et al. (1975) en Durnin en Womersley (1974)) is gebruik om liggaamsvetinhoud te bereken, met die doel om ‘n belowende metode te vind om veranderinge in liggaamssamestelling te meet in ‘n kliniese omgewing. Verskeie antropometriese metings is geneem, sowel as uitgesoekte hematologiese en lewenskwaliteitmetings (QoL) vir ‘n groep van agt deelnemers wat antiretrovirale medikasie ontvang het (ART groep) en ses deelnemers wat nie hierdie behandeling ontvang het nie (TN groep). Nuwe veranderlikes (binnebuikindikator (IAI) en die verhouding van persentasie van ideale liggaamsmassa tot persentasie van ideale armomtrek (%IBW:%IAC)) is ondersoek as moontlike aanwysers van lipodistrofie. Drie spesifieke tydpunte vir die ART groep en twee tydpunte vir die TN groep is gekies uit die verskeie tydpunte waarby metings geneem is, nl. basislyn (gedefinieer as die dag wat TN deelnemers in die studie opgeneem is en 0 tot 4 weke voor die begin van behandeling vir die ART deelnemers), korttermyn (2 tot 12 weke nadat behandeling begin is of na die basislyn meting) en lang-termyn (binne een en ‘n half jaar nadat behandeling begin is vir die ART groep). By die basislyn tydpunt het min van die ART en TN deelnemers se gemete veranderlikes verskil. Die ART en TN groepe het hoofsaaklik verskil ten opsigte van veranderlikes wat betrekking het op die arm, veral persentasie van ideale armomtrek (%IAC) en bo-arm vetarea (UAFA). Hierdie twee veranderlikes was beduidend laer in die ART groep as in die TN groep. CD4+ seltelling en lewenskwaliteit tellings het beduidend verbeter vir die ART deelnemers van die basislyn tot die lang-termyn tydpunt. Hierdie veranderinge is nie samehangend met veranderinge in spiermassa nie, maar eerder met sommige vetmassa veranderlikes. Deelnemers wat antiretrovirale medikasie ontvang het, het veranderinge getoon wat gedui het op ‘n verhoogde neerlegging van vet in die buikarea. Ten slotte is bevind dat antiretrovirale medikasie bygedra het tot die verbeterde lewenskwaliteit van die deelnemers en dat dit waarskynlik ook die omkeer van uittering van ten minste een deelnemer aangehelp het. Daar is ook bevind dat armverwante metinge gebruik kan word in die plattelandse kliniese omgewing om pasiënte suksesvol te monitor ten opsigte van VIGSverwante uittering. Die nuwe veranderlikes, IAI en %IBW:%IAC kan moontlik gebruik word om lipodistrofie-verwante veranderings te meet en die gebruik van hierdie veranderlikes behoort ondersoek te word in verdere navorsing.

El uso de la terapia HAART (Highly-Active-Antiretroviral-Therapy), puede dar lugar a múltiples efectos secundarios. El más frecuente de ellos es el denominado HALS (“HIV-infection, HAARTtreatment- associated-lipodystrophy-syndrome”) que comprende alteraciones como la lipoatrofia periferica; un aumento de tejido adiposo visceral o la lipomatosis del tejido adiposo. Además, estas alteraciones fisiológicas pueden ir acompañadas de alteraciones metabólicas. Para saber la aportación individual de algunos fármacos al desarrollo del síndrome lipodistrófico HALS se realizó un estudio de los efectos de Efavirenz, Nevirapina (NNRTIs) y Kaletra (PI) sobre adipocitos primarios de linaje blanco en cultivo. Efavirenz, que no era considerado un fármaco asociado al síndrome lipodistrófico, es capaz de inhibir la adipogénesis con mayor potencia que Kaletra y Nevirapina. Ninguno de estos fármacos provoca toxicidad mitocondrial por lo que sus efectos ocurren en ausencia de toxicidad mitocondrial. Tanto efavirenz como kaletra reducen la secreción de adipoquinas y aumentan la expresión y secreción de citoquinas relacionadas con la inflamación, pero estos efectos siempre son mayores con el EFV mientras la Nevirapina parece no afectar a este tipo de secreciónes. Para estudiar las características moleculares de los diferentes depósitos de tejido adiposo con comportamiento opuesto como el tejido adiposo subcutáneo lipoatrófico y el tejido adiposo visceral lipohipertrófico o el tejido adiposo lipomatoso de las “buffalo-hump” de los pacientes se han comparado características moleculares de ellas con tejido adiposo de individuos control. En la comparación entre el tejido adiposo subcutáneo lipoatrófico y el visceral se ha observado que en ambos casos el tejido adiposo presenta alteraciones similares en la función mitocondrial. En cambio el descenso de marcadores de adipogénesis observado en el tejido subcutáneo de pacientes no se reproduce en el tejido visceral. Este hecho, acompañado de diferencias en el perfil de expresión de marcadores de inflamación (que parece más leve en el tejido visceral), podría explicar el comportamiento opuesto de ambos depósitos en pacientes. El estudio en el que se compararon el tejido adiposo lipomatosos de las “buffalo-hump” y el tejido adiposo subcutáneo lipoatrófico de pacientes infectados por el HIV- indica que el tejido adiposo de las “buffalo-hump” presenta alteraciones especificas en la expresión génica respecto al tejido lipoatrófico en las que destaca una expresión normal de genes adipogénicos. Así mismo, el tejido lipomatoso es capaz de expresar UCP1, un gen característico del tejido adiposo marrón, y su capacidad proliferativa concuerda más con un fenotipo del tipo marrón, por lo que se puede decir que estos adipocitos tienen un fenotipo intermedio entre blanco y marrón que se mantiene cuando este tejido lipomatoso es utilizado para trasplante autólogo a la zona facial lipoatrófica en la que mantiene la proliferación desarrollándose el síndrome hámster. No se observan diferencias en las alteraciones mitocondriales observadas en ambos tejidos. Por otra parte la ausencia de un estado de inflamación local en BH podría explicar en parte este comportamiento diferente de ambos tejidos. Además se ha observado que los pacientes muestran niveles elevados de FGF21 y disminuidos de FGF19 (dos agentes homeostaticos) respecto a los controles. Estas diferencias con los controles se acentúan a medida que los pacientes infectados por el virus HIV-1 pasan de ser no tratados a tratados y aun más al desarrollar la lipodistrofia. Los niveles de FGF21 en suero se correlacionaban con indicadores de sensibilidad a insulina o marcadores de síndrome metabólico así como con marcadores de daño hepático que podrían estar relacionados con esteatosis hepática. Los niveles disminuidos en suero de FGF19 se correlacionan negativamente con parámetros indicativos de resistencia a insulina. Además se ha descrito en esta tesis que los receptores de estos agentes endocrinos FGFR1 y β-Klotho aparecen disminuidos en el tejido adiposo de los pacientes infectados por el virus HIV-1. / Molecular basis of adipose tissue alterations and metabolic disturbances associated to HIV-1-infected lipodystrophic patients Disturbances in adipose tissue in HIV-1-infected patients undergoing HAART involve a complex set of alterations known as HAART-associated-lipodystrophy-syndrome (HALS). In most cases, lipoatrophy occur in the face, arms and legs. An enlargement of visceral adipose tissue, reminiscent of visceral obesity, is present often in combination with peripheral lipoatrophy. Lipomatosis is also commonly found in HALS, usually as an enlargement in the dorso-cervical area (buffalo-hump), although the development of lipomas in distinct anatomical sites has also been reported. This adipose tissue redistribution is associated with systemic metabolic alterations such as insulin resistance or dyslipidemia. To determine the individual contribution to HALS of some HAART-prescriptioned drugs, we performed an assessment of the effects of efavirenz, nevirapine and Kaletra on human cultured adipocytes. Our results support the fact that efavirenz and Kaletra impair adipogenesis, reduce the release of adipokines and increase the expression and release of inflammation-related cytokines, while nevirapine does not. Overall, those effects are greater in the case of efavirenz. We compared as well the molecular signature of subcutaneous lipoatrophic, visceral lipohipertrophic and dorso-cervical lipomatous adipose tissues from patients in order to determine the molecular basis causing these fat depots to behave in an opposite way. All fat biopsies from patients exhibited alterations in mitochondrial function marker genes. Visceral and “buffalo hump” fat didn’t show any alterations in the expression of adipogenesis marker genes when compared to healthy controls, while subcutaneous fat showed lower levels. The inflammatory profile was normal in “buffalo hump”, whereas visceral and subcutaneous adipose tissue depots exhibited a distinct, more exacerbated, pro-inflammatory profile. These differences could be part of the explanation of the mentioned different behavior. The serum levels of novel homeostatic agents FGF19 and FGF21 was also assessed in samples from lipodystrophic patients. FGF21 levels were significantly higher in patients and correlated positively with markers of insulin resistance, metabolic syndrome and hepatic damage. On the other hand, FGF19 levels were significantly lower in patients and correlated negatively with markers of insulin resistance. We studied the transcription level of FGF receptors in adipose tissue as well, resulting in a lower expression in biopsies from HALS patients.